Page 3 - Beckley Psytech News Today

At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change with the US FDA’s acceptance of a New Drug ...

London, Feb. 07, 2024 (GLOBE NEWSWIRE) -- An international clinical trial which is investigating a novel synthetic formulation of the psychedelic...

Q1 Fiscal 2024 Highlights Gross profit of $2.1 million, an 18.8% increase over Q4 2023 Revenue of $5.9 million, a 3.0% decline over Q4 2023 Reduced operating...

Q1 Fiscal 2024 Highlights Gross profit of $2.1 million, an 18.8% increase over Q4 2023Revenue of $5.9 million, a 3.0% decline over Q4 2023Reduced operating expenditures of 19.9% over Q4 2023Cash...

The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has attracted growing attention and investment. 

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub

(Bloomberg) -- Atai Life Sciences NV agreed to acquire a stake in smaller rival Beckley Psytech to expand its portfolio of drug candidates for the treatment of mental health conditions. Most Read from BloombergConfidential Jeffrey Epstein Documents Unsealed by New York CourtFed Sees Rates Staying High for Some Time With Cuts Eyed in 2024Saving the Panama Canal Will Take Years and Cost Billions, If It’s Even PossibleTech Stocks Log Four-Day Losing Streak, Bonds Rise: Markets WrapIran Blast...

Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions.

Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of…